Literature DB >> 29029280

Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.

Oliver A Cornely, Michael N Robertson, Shariq Haider, Andrew Grigg, Michelle Geddes, Mickael Aoun, Werner J Heinz, Issam Raad, Urs Schanz, Ralf G Meyer, Sarah P Hammond, Kathleen M Mullane, Helmut Ostermann, Andrew J Ullmann, Stefan Zimmerli, M L P S Van Iersel, Deborah A Hepler, Hetty Waskin, Nicholas A Kartsonis, Johan Maertens.   

Abstract

Entities:  

Year:  2017        PMID： 29029280     DOI： 10.1093/jac/dkx382

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  3 in total

1.  A Population Pharmacokinetic Model for a Solid Oral Tablet Formulation of Posaconazole.

Authors:  Marlou L P S van Iersel; Stefaan Rossenu; Rik de Greef; Hetty Waskin
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

2.  Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability.

Authors:  Haiyan Li; Yudong Wei; Shuang Zhang; Lin Xu; Jun Jiang; Yanping Qiu; Eric Mangin; Xu Min Zhao; Shuang Xie
Journal:  Clin Drug Investig       Date:  2019-11       Impact factor: 3.580

3.  Development of UPLC-MS/MS Method for Studying the Pharmacokinetic Interaction Between Dasatinib and Posaconazole in Rats.

Authors:  Suili Yang; Xiaoshan Zhang; Yuzhen Wang; Congcong Wen; Chenxiang Wang; Ziye Zhou; Guanyang Lin
Journal:  Drug Des Devel Ther       Date:  2021-05-24       Impact factor: 4.162
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.